News

ICON6 ovarian cancer results may resurrect cediranib


 

AT THE EUROPEAN CANCER CONGRESS 2013

Prof. Ledermann and his coauthors reported no relevant disclosures. AstraZeneca provided the study drug. Britain’s Medical Research Council sponsored the trial.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Routine bilateral salpingectomy with hysterectomy gains acceptance
MDedge Hematology and Oncology
CDC urges doctors to help patients quit smoking
MDedge Hematology and Oncology
Maintenance pazopanib delays progression of advanced ovarian cancer
MDedge Hematology and Oncology
Cervical cancer screening with acetic acid saves lives
MDedge Hematology and Oncology
Bevacizumab plus chemotherapy extends cervical cancer survival
MDedge Hematology and Oncology
CDC study finds 56% drop in HPV infections
MDedge Hematology and Oncology
Olaparib maintenance of most benefit in BRCA mutation carriers
MDedge Hematology and Oncology
Weekly chemo offers quality-of-life edge in advanced ovarian cancer
MDedge Hematology and Oncology
Biweekly 5-fluorouracil cream beat back cervical neoplasia
MDedge Hematology and Oncology
TRINOVA-1 signals new direction in ovarian cancer
MDedge Hematology and Oncology